Bupivacaine Verus Pethidine for Post Cesarean Section Pain Relief
NCT ID: NCT03652116
Last Updated: 2018-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
78 participants
INTERVENTIONAL
2017-04-21
2018-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bupivacaine Group
Patients delivered by cesarean section followed by wound infiltration by bupivacaine.
Wound infiltration by Bupivacaine
Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
Pethidine Group
Patients delivered by cesarean section followed by wound infiltration by pethidine.
Wound infiltration by Pethidine
Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Wound infiltration by Bupivacaine
Subcutaneous and subrectal infiltration with 0.25 % Bupivacaine diluted in 20 ml normal saline before closure of the wound
Wound infiltration by Pethidine
Subcutaneous and subrectal infiltration with 50 mg pethidine diluted in 20 ml normal saline before closure of the wound
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age: 37-40 weeks.
* Type of anaesthesia: Spinal anaesthesia.
* No past history of any medical disorder or other medical complications during pregnancy.
Exclusion Criteria
* Women delivered vaginally.
* Women delivered under general anaesthesia.
* Women with known neurological or psychological disease.
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sarah Safwat
Lecturer in Obstetrics and Gynecology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mohamed Samy, MD
Role: STUDY_DIRECTOR
M Samy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain SHams Maternity Hospital
Cairo, Abbaseya, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PostCSLA
Identifier Type: -
Identifier Source: org_study_id